“…Predictors that have shown promise are similar to predictors seen in other chemical dependency treatment programs and include pre-treatment psychosocial functioning (Farrell et al, 1994), severity of chemical dependency, and comorbidity (Avants et al, 2000;Brown et al, 1998;Hoegerman & Schnoll, 1991;McLellan et al, 1994;McLellan, Luborsky, Woody, Druley, & O'Brien, 1983). High rates of comorbidity have been found in drug-using populations (Avants, Warburton, & Margolin, 2000;Brienza et al, 2000;Khantzian & Treece, 1985;Kissin, Svikis, Morgan, & Haug, 2001) and have been associated with poorer treatment outcome (Rounsaville, Kosten, Weissman, & Kleber, 1986;Strain, 2002). Lifetime prevalence rates for mixed gender and all female samples of any psychiatric disorder have typically ranged from 40% (Brooner, King, Kidorf, Schmidt, & Bigelow, 1997;Kissin, et al, 2001;Strain, 2002) to 90.8% (Rounsaville et al, 1986), with Major Depressive Disorder or Mood Disorder being the most commonly reported Axis I diagnoses in females.…”